Transvenous pulmonary chemoembolization (TPCE) for palliative or neoadjuvant treatment of lung metastases
- 107 Downloads
To retrospectively evaluate tumor response, local tumor control, and patient survival after the treatment of pulmonary metastases using transpulmonary chemoembolization (TPCE) in palliative and neoadjuvant intent.
Materials and methods
One hundred forty-three patients (mean age 56.7 ± 13.4 years) underwent repetitive TPCE (mean number of sessions 5.8 ± 2.9) between June 2005 and April 2017 for the treatment of unresectable lung metastases, not responding to systemic chemotherapy. Patients had predominant lung metastases with bilateral lung involvement in 80.4% of the cases. Regional delivery of the chemotherapeutic agents was performed through selective catheterization of the tumor-supplying pulmonary arteries with subsequent injection of iodized oil and microspheres. Patients, who underwent subsequent ablation (n = 51), either for all lesions (complete) or dominant lesions (incomplete), constituted the neoadjuvant group, and those who underwent TPCE alone represented the palliative treatment intent (n = 92). The response was assessed according to the revised Response Evaluation Criteria in Solid Tumors (RECIST).
Partial response was achieved in 11.9% (n = 17), stable disease in 66.4% (n = 95), and progressive disease in 21.7% (n = 31). The mean survival time and time to progression were 24.5 ± 1.7 and 7.5 ± 0.5 months, respectively. The mean survival time was shorter for the palliative group (19.7 ± 2), compared to the neoadjuvant group (30.1 ± 2.6 months). The use of TPCE alone or with incomplete ablation had a significantly increased hazard of death of 4.6- (p = 0.002) and 3.1-fold (p = 0.027), respectively, in comparison with TPCE with subsequent complete ablation.
TPCE has the potential to improve local tumor control and to prolong survival with a neoadjuvant potential when combined with ablation therapy.
• Transpulmonary chemoembolization (TPCE) is a locoregional technique for delivering chemotherapy in higher intratumoral concentrations and with reduced systemic toxicity.
• TPCE can be an alternative treatment for patients with pulmonary metastases who failed prior systemic chemotherapy or with post-operative recurrence.
• The current retrospective study revealed that TPCE is a feasible treatment option for patients with unrespectable lung secondaries in both palliative and neoadjuvant intent and has the potential of improving local control and prolonging survival.
KeywordsTherapeutic chemoembolization Lung neoplasms Interventional radiology Palliative care Neoadjuvant therapy
Computed tomography angiography
Isolated lung perfusion
Multidetector computed tomography
Magnetic resonance imaging
Response Evaluation Criteria in Solid Tumors
Mean time to progression
The authors state that this work has not received any funding.
Compliance with ethical standards
The scientific guarantor of this publication is Prof. Dr. Thomas J. Vogl, Department of Diagnostic and Interventional Radiology, Goethe-University, Frankfurt/Main.
Conflict of interest
The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
Statistics and biometry
No complex statistical methods were necessary for this paper.
Written informed consent was not required for this study because of its retrospective nature.
Institutional Review Board approval was obtained.
• Performed at one institution
- 1.Van Meerbeeck JP, Gosselin R, Duyck P (2007) Lung metastases: epidemiology, clinical presentation and imaging. In: Van Schil P (ed) Lung metastases and isolated lung perfusion. Nova Science Publishers, Inc, HauppaugeGoogle Scholar
- 3.Fan J, Chen D, Du H, Shen C, Che G (2015) Prognostic factors for resection of isolated pulmonary metastases in breast cancer patients: a systematic review and meta-analysis. J Thorac Dis 7:1441–1451Google Scholar
- 4.Friedel G, Pastorino U, Buyse M et al (1999) Resection of lung metastases: long-term results and prognostic analysis based on 5206 cases--the International Registry of Lung Metastases. Zentralbl Chir 124:96–103Google Scholar
- 11.Jiang GM, Zhao JW, Chen YX, Tian F (2006) Blood supply of pulmonary metastases and its clinical significance. Ai Zheng 25:885–887Google Scholar
- 15.Schneider P, Kampfer S, Loddenkemper C, Foitzik T, Buhr HJ (2002) Chemoembolization of the lung improves tumor control in a rat model. Clin Cancer Res 8:2463–2468Google Scholar
- 17.Pohlen U, Rieger H, Meyer BT et al (2007) Chemoembolization of lung metastases--pharmacokinetic behaviour of carboplatin in a rat model. Anticancer Res 27:809–815Google Scholar
- 29.Treasure T, Fiorentino F, Scarci M, Moller H, Utley M (2012) Pulmonary metastasectomy for sarcoma: a systematic review of reported outcomes in the context of Thames Cancer Registry data. BMJ Open 2. https://doi.org/10.1136/bmjopen-2012-001736
- 33.Inoue Y, Miki C, Hiro J et al (2005) Improved survival using multi-modality therapy in patients with lung metastases from colorectal cancer: a preliminary study. Oncol Rep 14:1571–1576Google Scholar
- 35.Welter S, Arfanis E, Christoph D et al (2017) Growth patterns of pulmonary metastases: should we adjust resection techniques to primary histology and size? Eur J Cardiothorac Surg. https://doi.org/10.1093/ejcts/ezx063
- 36.Akhan O, Güler E, Akýncý D, Çiftçi T, Köse IÇ (2016) Radiofrequency ablation for lung tumors: outcomes, effects on survival, and prognostic factors. Diagn Interv Radiol 22:65–71Google Scholar
- 37.Pfannschmidt J, Egerer G, Bischof M, Thomas M, Dienemann H (2012) Surgical intervention for pulmonary metastases. Dtsch Arztebl Int 109:652–658Google Scholar